← Back to Search

Cannabinoid

Full-Spectrum Hemp-Derived CBD (fsCBD) for Depression (ARCTiC Trial)

Phase 2

Waitlist Available

Research Sponsored by University of Colorado, Boulder

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged ≥25 years at Visit 1 (Baseline)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 4 weeks, 8 weeks

Awards & highlights

ARCTiC Trial Summary

This trial aims to study the effects of hemp-derived CBD with and without THC on symptoms like pain, sleep, mood, and cognitive function in cancer patients. The study will compare these effects with a placebo

Who is the study for?

This trial is for cancer patients experiencing pain, sleep disturbances, and mood issues. Participants should be interested in using hemp-derived CBD to manage these symptoms. Specific eligibility criteria are not provided, but typically include factors like age range, cancer type/stage, and overall health status.Check my eligibility

What is being tested?

The study compares the effects of two types of Cannabidiol (CBD) - one with THC (fsCBD) and one without THC (bsCBD), against a placebo. It aims to assess their impact on sleep quality, pain levels, mood changes, cognitive function, and life quality in 185 cancer patients.See study design

What are the potential side effects?

Potential side effects may include cognitive impairment due to THC content in fsCBD. Other common cannabis-related side effects could involve dizziness, dry mouth, altered appetite or mood changes; however specific side effects will be monitored throughout the trial.

ARCTiC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 25 years old or older.

ARCTiC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 4 weeks, 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 4 weeks, 8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4 weeks, 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cognitive Function

Depression/Anxiety

Drug Effects

+12 more

Secondary outcome measures

Polypharmacy

ARCTiC Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Full-Spectrum Hemp-Derived CBD (fsCBD)Experimental Treatment1 Intervention

8 weeks of use of a daily dose of cannabis (200mg CBD/4mg THC)

Group II: Broad-Spectrum Hemp-Derived CBD (bsCBD)Experimental Treatment1 Intervention

8 weeks of use of a daily dose of cannabis (200mg CBD)

Group III: PlaceboPlacebo Group1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Colorado, BoulderLead Sponsor

119 Previous Clinical Trials

29,009 Total Patients Enrolled

13 Trials studying Depression

3,572 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA granted approval for Full-Spectrum Hemp-Derived CBD (fsCBD)?

"Based on our evaluation, Full-Spectrum Hemp-Derived CBD (fsCBD) has been assigned a safety rating of 2 by our team at Power. This rating is due to the ongoing Phase 2 trial which indicates some level of safety data but no evidence yet supporting efficacy."

Answered by AI

Is the enrollment process currently ongoing for individuals interested in participating in this trial?

"Per clinicaltrials.gov, this study is presently not enrolling participants. The trial was initially listed on 3/1/2024 and last updated on 2/16/2024. Despite its current inactivity, there are a total of 1891 other studies actively seeking candidates for participation."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cannabis for Palliative Care in Cancer

Angela Bryan 2024. "Cannabis for Palliative Care in Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06266611.

All > Cbd > Epidiolex